5 completed. 4 Phase 2, 1 Phase 1.
| Phase | Trials | Status |
|---|---|---|
| Phase 2 | 4 | Completed 4 |
| Phase 1 | 1 | Completed 1 |
Follow NYX-2925: new trials by email Literature Review of NYX-2925 trials Research Report on NYX-2925
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Efficacy and Safety of NYX-2925 in Subjects With Neuropathic Pain Associated With Diabetic Peripheral Neuropathy (DPN) NYX-2925 50 mg, Placebo - Diabetic Peripheral Neuropathic Pain | Phase 2 | Completed | Aptinyx | 228 | 2019-11-12 | 2023-04-28 |
| Efficacy and Safety of NYX-2925 in Subjects With Fibromyalgia NYX-2925, Placebo - Fibromyalgia | Phase 2 | Completed | Aptinyx | 310 | 2019-11-12 | 2023-04-28 |
| Evaluate the Efficacy and Safety of NYX-2925 in Subjects With Fibromyalgia NYX-2925, Placebo oral capsule - Fibromyalgia | Phase 2 | Completed | Aptinyx | 22 | 2017-08-14 | 2022-09-16 |
| Efficacy and Safety of NYX-2925 in Subjects With Neuropathic Pain Associated With Diabetic Peripheral Neuropathy NYX-2925, Placebo - Diabetic Peripheral Neuropathy | Phase 2 | Completed | Aptinyx | 301 | 2017-06-27 | 2020-06-09 |
| Safety, Tolerability, PK of Oral NYX-2925 in Healthy Volunteers NYX-2925 - Healthy Volunteers | Phase 1 | Completed | Aptinyx | 84 | 2016-07-01 | 2017-04-05 |
Fibromyalgia (2) · Diabetes Mellitus, Type 2 (1) · Neuralgia (1)
Aptinyx (5)
United States (5)
Carlos Sanabria, MD (1) · Laurel Sindelar (1)